Ionis Pharmaceuticals (IONS) Stock Forecast, Price & News

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IONS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View IONS analyst ratings or view top-rated stocks.

10 analysts have issued 1 year price targets for Ionis Pharmaceuticals' shares. Their IONS share price forecasts range from $27.00 to $67.00. On average, they expect the company's share price to reach $46.64 in the next year. This suggests a possible upside of 15.0% from the stock's current price.
View analysts price targets for IONS or view top-rated stocks among Wall Street analysts.

Ionis Pharmaceuticals' stock was trading at $37.77 on January 1st, 2023. Since then, IONS stock has increased by 7.4% and is now trading at $40.55.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our IONS earnings forecast.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) issued its quarterly earnings data on Wednesday, May, 3rd. The company reported ($0.87) earnings per share for the quarter, beating analysts' consensus estimates of ($1.00) by $0.13. The firm had revenue of $131 million for the quarter, compared to the consensus estimate of $126.88 million. Ionis Pharmaceuticals had a negative net margin of 56.85% and a negative trailing twelve-month return on equity of 57.58%. The business's quarterly revenue was down 7.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.46) earnings per share.

ETFs with the largest weight of Ionis Pharmaceuticals (NASDAQ:IONS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Direxion mRNA ETF (MSGR), First Trust NYSE Arca Biotechnology Index Fund (FBT), Invesco Dynamic Biotechnology & Genome ETF (PBE), Horizon Kinetics Medical ETF (MEDX), Franklin Genomic Advancements ETF (HELX), Virtus LifeSci Biotech Products ETF (BBP) and VanEck Morningstar SMID Moat ETF (SMOT).

Ionis Pharmaceuticals updated its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $597.65 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.98%), Clearbridge Investments LLC (3.77%), Price T Rowe Associates Inc. MD (2.75%), ARK Investment Management LLC (1.84%), BVF Inc. IL (1.79%) and Geode Capital Management LLC (1.45%). Insiders that own company stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, Brian Birchler, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends.

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IONS stock can currently be purchased for approximately $40.55.

Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $5.80 billion and generates $575.97 million in revenue each year. The company earns $-269,720,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis.

The company employs 660 workers across the globe.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for the company is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at wwalke@ionisph.com, or via fax at 760-603-2700.